| Autor: |
McSorley LM; Department of Medical Oncology, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., Tharmabala M; Department of Medical Oncology, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., Al Rahbi F; Department of Pathology, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., Keane F; Department of Medical Oncology, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., Evoy D; Department of Surgery, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., Geraghty JG; Department of Surgery, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., Rothwell J; Department of Surgery, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., McCartan DP; Department of Surgery, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., Greally M; Department of Medical Oncology, Beaumont Hospital, D04 T6F4 Dublin, Ireland., O'Connor M; Department of Medical Oncology, University Hospital Waterford, X91 ER8E Waterford, Ireland., O'Mahony D; Department of Medical Oncology, Bon Secours Hospital, T12 DV56 Cork, Ireland., Keane M; Department of Medical Oncology, Galway University Hospitals, H91 YR71 Galway, Ireland., Kennedy MJ; Department of Medical Oncology, St James's Hospital, D08 NHY1 Dublin, Ireland., O'Reilly S; Department of Medical Oncology, Cork University Hospital, T12 DC4A Cork, Ireland., Millen SJ; Exact Sciences UK Ltd., London EC4M 9AF, UK., Crown JP; Department of Medical Oncology, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., Kelly CM; Department of Medical Oncology, The Mater Misericordiae University Hospital, D07 R2WY Dublin, Ireland., Prichard RS; Department of Surgery, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., Quinn CM; Department of Pathology, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland.; School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland., Walshe JM; Department of Medical Oncology, St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland.; School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland. |
| Abstrakt: |
Background: This study, using real-world data, assesses the impact of RS testing on treatment pathways and the associated economic consequences of such testing. This paper pertains to lobular breast cancer. Methods: A retrospective, observational study was undertaken between 2011 and 2019 on a cross-section of hormone receptor-positive (HR+), HER2-negative, lymph node-negative, early-stage breast cancer patients. All patients had ILC and had RS testing in Ireland. The patient population is representative of the national population. Patients were classified as low (RS ≤ 25) or high (RS > 25) risk. Patients aged ≤50 were stratified as low (RS 0-15), intermediate (RS 16-25), or high risk (RS > 25). Results: A total of 168 patients were included, most of whom had grade 2 (G2) tumors ( n = 154, 92%). Overall, 155 patients (92.3%) had low RS (≤25), 12 (7.1%) had high RS (>25), and 1 (0.6%) had unknown RS status. In 29 (17.5%) patients aged ≤50 at diagnosis, RS was ≤15 in 16 (55%), 16-20 in 6 (21%), 21-25 in 5 (17%), >25 in 1 (3.5%), and unknown in 1 (3.5%). Post RS testing, 126 patients (78%) had a change in chemotherapy recommendation; all to hormone therapy. In total, only 35 patients (22%) received chemotherapy. RS testing achieved a 75% reduction in chemotherapy use, resulting in savings of €921,543.84 in treatment costs, and net savings of €387,283.84. Conclusions: The use of this test resulted in a 75% reduction in chemotherapy and a significant cost savings in our publicly funded health system. |
